Disruption of insulin receptor function inhibits proliferation in endocrine resistant breast cancer cells

The insulin-like growth factor (IGF) system is a well-studied growth regulatory pathway implicated in breast cancer biology. Clinical trials testing monoclonal antibodies directed against the type I IGF receptor (IGF1R) in combination with estrogen receptor-α (ER) targeting have been completed, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Jie Ying, LaPara, Kelly, Yee, Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982805/
https://www.ncbi.nlm.nih.gov/pubmed/26876199
http://dx.doi.org/10.1038/onc.2015.488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982805/
https://www.ncbi.nlm.nih.gov/pubmed/26876199
http://dx.doi.org/10.1038/onc.2015.488

Ejemplares similares